Clinton Group’s Avanos Medical AVNS Stock Holding History

Clinton Group’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-5,771	Closed	-$220K	–	573
2017 Q1	$220K	Buy	+5,771	New	+$225K	0.01%	848

Other funds holding AVNS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Clinton Group's AVNS Position: Q2 2017 in Review

Clinton Group sold out of Avanos Medical (AVNS) in Q2 2017, closing a stake of 5,771 shares — an estimated $220K sold.

Clinton Group first reported a position in AVNS in Q1 2017 and held it in 1 quarter. The position peaked at $220K in Q1 2017. 328 funds tracked by Wall St. Rank hold AVNS as of Q2 2017.

Clinton Group reported no remaining Avanos Medical position as of Q2 2017 after selling out during the quarter.
Clinton Group sold 5,771 Avanos Medical shares in Q2 2017, an estimated $220K.
Clinton Group first reported a position in Avanos Medical in Q1 2017 and held it in 1 quarter.
Clinton Group's Avanos Medical position peaked at $220K in Q1 2017.
328 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2017.

Based on Clinton Group's 13F filing for Q2 2017, filed 14 Aug 2017.